Senseonics Holdings, Inc. Common Stock (SENS)
Frequently Asked Questions About Senseonics Holdings, Inc. Common Stock (SENS)
Are there any clinical trials for Eversense?
Yes, Senseonics conducts various clinical trials to evaluate the Eversense CGM system's effectiveness, safety, and potential new features. These studies are crucial for obtaining regulatory approvals and for continuous improvement of the technology, ensuring that it meets the evolving needs of patients and healthcare providers.
How does Senseonics support patients and healthcare providers?
Senseonics supports patients and healthcare providers by offering comprehensive resources including educational materials, training sessions, and customer support to ensure effective usage of the Eversense CGM system. The company's initiatives focus on improving patient outcomes and enhancing diabetes management through reliable and advanced technology.
How does the company engage with the diabetes community?
Senseonics engages with the diabetes community through partnerships with healthcare professionals, participation in diabetes-related events, and fostering relationships with patient advocacy organizations. By actively listening to the needs of patients and providers, Senseonics seeks to improve their product offerings while contributing positively to diabetes care.
How does the company prioritize research and development?
Research and development are central to Senseonics’ strategy, with the company dedicating significant resources to innovate and enhance its product offerings. By focusing on user feedback, clinical data, and technological advancements, Senseonics aims to develop cutting-edge solutions that can better serve the diabetes community.
How does the Eversense CGM system work?
The Eversense CGM system works by implanting a small glucose-sensing device beneath the skin, which measures glucose levels in the interstitial fluid. The data collected by the sensor is transmitted wirelessly to a smartwatch or mobile app, allowing users to monitor their glucose levels in real time and receive alerts for any significant changes.
How is Senseonics technology different from traditional CGM systems?
Senseonics' technology is distinct from traditional continuous glucose monitoring systems primarily due to its implantable sensor that lasts up to 90 days. Traditional CGM systems typically require sensor changes every 7 to 14 days. The Eversense system's longer lifespan, combined with features like real-time monitoring and alerts, provides a more convenient solution for patients managing their diabetes.
Is the Eversense system approved by regulatory bodies?
Yes, the Eversense CGM system has received approval from the U.S. Food and Drug Administration (FDA) and regulatory agencies in Europe. This approval validates the system's safety and efficacy, enabling it to be used by individuals with diabetes to manage their condition more effectively.
What are the company's goals for the future?
Senseonics aims to become a leader in glucose monitoring technology, with goals focusing on the development of next-generation CGM systems that may allow for longer sensor life and improved accuracy. The company also intends to expand its market presence internationally and increase product adoption to help more patients manage their diabetes effectively.
What are the company’s recent developments?
Recent developments at Senseonics include advancements in its Eversense CGM technology, such as ongoing clinical trials for longer-lasting sensors, enhancements to the mobile application features, and potential expansions into new markets. The company continually seeks to innovate and improve its product offerings to better serve individuals with diabetes.
What does Senseonics Holdings, Inc. do?
Senseonics Holdings, Inc. develops innovative continuous glucose monitoring (CGM) systems for people with diabetes. Its flagship product is the Eversense system, which incorporates a small, implantable sensor that monitors glucose levels for up to 90 days. The company's technology aims to provide real-time glucose data to patients, enhancing diabetes management and improving quality of life.
What financing options does Senseonics explore?
Senseonics explores various financing options to support its business growth, including equity financing, partnerships, collaborations with pharmaceutical companies, and grants. These funding avenues enable the company to invest in research and development, expand its product portfolio, and reach more patients who benefit from advanced diabetes management solutions.
What is the Eversense system?
The Eversense system is a continuous glucose monitoring (CGM) device developed by Senseonics, which consists of an implantable sensor, a transmitter worn on the skin, and a mobile app for monitoring glucose levels. Unlike traditional CGM systems, Eversense's implantable sensor can last for up to 90 days, significantly reducing the need for frequent replacements and improving user convenience.
What is the significance of continuous glucose monitoring for diabetes management?
Continuous glucose monitoring is significant for diabetes management because it provides real-time insights into glucose levels, allowing individuals to make informed decisions about their diet, activity, and insulin use. This proactive approach can help prevent dangerous spikes or drops in blood sugar, ultimately leading to better overall health outcomes for those with diabetes.
What is the stock market performance of Senseonics?
Senseonics Holdings, Inc. trades on the New York Stock Exchange under the ticker symbol SENS. The company's stock market performance can vary widely, influenced by factors such as product developments, regulatory approvals, and overall market conditions in the healthcare and medical devices sector.
What partnerships does Senseonics have?
Senseonics has established various partnerships with healthcare organizations, academia, and technology companies to further its mission of improving diabetes management. These collaborations often involve research, clinical trials, and co-development opportunities that can enhance the capabilities and outreach of its continuous glucose monitoring technologies.
When was Senseonics Holdings, Inc. founded?
Senseonics Holdings, Inc. was founded in 2013. Since its inception, the company has focused on advancing diabetes management technology, culminating in the introduction of its Eversense continuous glucose monitoring system that provides significant innovations over traditional methods.
Where is Senseonics Holdings, Inc. headquartered?
Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, USA. This location plays a pivotal role in its operations, allowing the company to leverage proximity to key industry stakeholders, researchers, and healthcare professionals in the development of its diabetes management technologies.
Who are the key executives at Senseonics?
Some of the key executives at Senseonics include the CEO and members of the executive management team with extensive backgrounds in the medical technology and healthcare industries. These leaders drive the company's vision and strategic direction, ensuring that Senseonics remains at the forefront of diabetes management innovation.
Who are the target users for the Eversense CGM system?
The target users for the Eversense CGM system are individuals diagnosed with diabetes, particularly those requiring continuous glucose monitoring to manage their condition. This includes people with type 1 diabetes, as well as those with type 2 diabetes who may benefit from more precise glucose monitoring for better management.
What is the current price of Senseonics Holdings, Inc. Common Stock?
The current price of Senseonics Holdings, Inc. Common Stock is 0.6546
When was Senseonics Holdings, Inc. Common Stock last traded?
The last trade of Senseonics Holdings, Inc. Common Stock was at 6:30 pm EDT on April 2nd, 2025
What is the market capitalization of Senseonics Holdings, Inc. Common Stock?
The market capitalization of Senseonics Holdings, Inc. Common Stock is 387.93M
How many shares of Senseonics Holdings, Inc. Common Stock are outstanding?
Senseonics Holdings, Inc. Common Stock has 592.63M shares outstanding.